Russia to Increase Expenditure on Subsidized Medicines by 6 Billion Rubles in 2025

0
422
At a gathering of the State Duma Committee on Health Protection, Russian Health Minister Mikhail Murashko announced plans to increase funding for subsidized medications for specific citizen groups by 6.1 billion rubles in 2025.
Murashko announced at the State Duma Committee on Health Protection meeting on Thursday that the primary expense category is drug provision, with plans to increase funding for specific groups of citizens’ medications by 6.1 billion rubles. He stated that the draft budget allocates 1 trillion 542 billion rubles for the implementation of the state program “Healthcare Development” in 2025. In the following years, the funding will increase to 1 trillion 555 billion rubles in 2026 and 1 trillion 606 billion rubles in 2027.
In relation to the 2024 indicators, spending on the implementation of this state program has been increased by 207 billion rubles, Interfax writes. Murashko also reported that the total amount of funds allocated for the implementation of the activities of the national project “Long and Active Life” will amount to 788 billion rubles, including: 369 billion rubles in 2025, 284 billion rubles in 2026 and 284 billion rubles in 2027.
As part of the federal project “Infrastructure Development”, it is planned to allocate 174 billion rubles for 59 medical capital construction projects in Russia, the minister noted. “It is planned to increase spending on equipment, including new entities. This concerns vascular centers of new entities and oncology dispensaries,” Murashko added.
At the meeting, he also added that Russian scientists are developing two drugs to combat tuberculosis, as well as new vaccines for the prevention of the disease.
“Today we are developing two drugs that will allow us to fight and improve the outcomes of tuberculosis treatment, and new vaccines for the prevention of tuberculosis.There is a great deal of interest in them, including from the international community. That is why we are currently developing such drugs, that is why we are definitely keeping this in our focus,” he said at a meeting of the State Duma Committee on Health Protection.”